Genomic evidence for recent positive selection at the human MDR1 gene locus.
暂无分享,去创建一个
Kun Tang | K. Tang | S. Chong | Caroline G L Lee | E. Lee | Samuel S Chong | L. Wong | Edmund J D Lee | Li Peng Wong | Caroline G. L. Lee
[1] M. Fromm,et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.
[2] U. Brinkmann,et al. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels , 2001, The Pharmacogenomics Journal.
[3] Werner Siegmund,et al. The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.
[4] Michael F. Hammer,et al. A recent common ancestry for human Y chromosomes , 1995, Nature.
[5] M. Stoneking,et al. Neandertal DNA Sequences and the Origin of Modern Humans , 1997, Cell.
[6] Jan Stankiewicz,et al. Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease. , 2003, Pharmacogenetics.
[7] A. Seelig. How does P-glycoprotein recognize its substrates? , 1998, International journal of clinical pharmacology and therapeutics.
[8] F. Sharom,et al. Interaction of the P-glycoprotein Multidrug Transporter with Peptides and Ionophores (*) , 1995, The Journal of Biological Chemistry.
[9] Lewontin Rc,et al. Annotation: the analysis of variance and the analysis of causes. , 1974 .
[10] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[11] I. Pastan,et al. Effect of ABC transporters on HIV‐1 infection: inhibition of virus production by the MDR1 transporter , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[12] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[13] Yusuke Nakamura,et al. Gene-based SNP discovery as part of the Japanese Millennium Genome Project: identification of 190 562 genetic variations in the human genome , 2002, Journal of Human Genetics.
[14] J. Kigawa,et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. , 2001, The Journal of pharmacology and experimental therapeutics.
[15] M. Eichelbaum,et al. Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease. , 2002, Pharmacogenetics.
[16] M. Gottesman,et al. HIV-1 protease inhibitors and the MDR1 multidrug transporter. , 1998, The Journal of clinical investigation.
[17] U. Brinkmann,et al. Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.
[18] S. Higuchi,et al. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. , 2001, Pharmacogenetics.
[19] A. Schinkel,et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. , 1996, The Journal of clinical investigation.
[20] U. Brinkmann,et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. , 2003, Gastroenterology.
[21] M. Gottesman,et al. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. , 2002, Molecular pharmacology.
[22] S. Liu-Cordero. Patterns of linkage disequilibrium in the human genome , 2002 .
[23] J. Pritchard,et al. Linkage disequilibrium in humans: models and data. , 2001, American journal of human genetics.
[24] A. Chakravarti,et al. Linkage disequilibrium and haplotype diversity in the genes of the renin-angiotensin system: findings from the family blood pressure program. , 2003, Genome research.
[25] E. Schuetz,et al. The MDR1 polymorphisms at exons 21 and 26 predict steroid weaning in pediatric heart transplant patients. , 2002, Human immunology.
[26] L R Cardon,et al. Extent and distribution of linkage disequilibrium in three genomic regions. , 2001, American journal of human genetics.
[27] D. Nelson,et al. Haplotypes at ATM identify coding-sequence variation and indicate a region of extensive linkage disequilibrium. , 2000, American journal of human genetics.
[28] Christian Meisel,et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. , 2002, British journal of clinical pharmacology.
[29] R. Kim,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.
[30] M. Kasuga,et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. , 2002, Biological & pharmaceutical bulletin.
[31] J. Stephens,et al. Haplotype Variation and Linkage Disequilibrium in 313 Human Genes , 2001, Science.
[32] U. Hofmann,et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.
[33] S. Cichon,et al. Can long-range microsatellite data be used to predict short-range linkage disequilibrium? , 2002, Human molecular genetics.
[34] L. Excoffier,et al. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. , 1995, Molecular biology and evolution.
[35] Pardis C Sabeti,et al. Linkage disequilibrium in the human genome , 2001, Nature.
[36] Yoshinori Morita,et al. MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.
[37] P. Joyce,et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.
[38] Pardis C Sabeti,et al. Detecting recent positive selection in the human genome from haplotype structure , 2002, Nature.
[39] R. Lewontin,et al. Annotation: the analysis of variance and the analysis of causes. , 2006, American journal of human genetics.
[40] U. Brinkmann,et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[41] Marek Kimmel,et al. Haplotype and linkage disequilibrium architecture for human cancer-associated genes. , 2002, Genome research.
[42] I. Pastan,et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. , 1998, Biochemistry.
[43] Benjamin Yakir,et al. Linkage disequilibrium patterns of the human genome across populations. , 2003, Human molecular genetics.
[44] Richard R. Hudson,et al. Generating samples under a Wright-Fisher neutral model of genetic variation , 2002, Bioinform..
[45] P. Sonneveld,et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.
[46] E. Schuetz,et al. Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
[47] Kun Tang,et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. , 2002, Pharmacogenetics.
[48] Keizo Sugimachi,et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene , 2002, Transplantation.
[49] M. Alary,et al. Allele frequency of three functionally active polymorphisms of the MDR-1 gene in high-risk HIV-negative and HIV-positive Caucasians. , 2002, AIDS.
[50] R. Kim,et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. , 2002, Cancer research.
[51] P. Borst,et al. What have we learnt thus far from mice with disrupted P-glycoprotein genes? , 1996, European journal of cancer.
[52] S. Pääbo,et al. Mitochondrial genome variation and the origin of modern humans , 2000, Nature.
[53] U. Brinkmann,et al. Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. , 2002, Journal of the American Society of Nephrology : JASN.
[54] M. Fromm,et al. Genetic polymorphisms of the human MDR1 drug transporter. , 2003, Annual review of pharmacology and toxicology.
[55] P. Deloukas,et al. Comparison of human genetic and sequence-based physical maps , 2001, Nature.
[56] A. Puri,et al. P‐glycoprotein‐overexpressing multidrug‐resistant cells are resistant to infection by enveloped viruses that enter via the plasma membrane 1 , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[57] D. Goldstein,et al. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. , 2003, The New England journal of medicine.
[58] Y. Cheung,et al. MDR1, the blood–brain barrier transporter, is associated with Parkinson’s disease in ethnic Chinese , 2004, Journal of Medical Genetics.
[59] K. Tang,et al. Simultaneous genotyping of seven single-nucleotide polymorphisms in the MDR1 gene by single-tube multiplex minisequencing. , 2003, Clinical chemistry.
[60] G R Lankas,et al. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. , 1998, Reproductive toxicology.